AndzonBio2 has announced the signature of agreements with the ALBORADA Drug Discovery Institute (ADDI) and Cambridge Enterprise to advance a new class of therapeutics targeting neuroinflammation.
Neuroinflammation is a central driver of multiple neurodegenerative and neurological conditions such as Parkinson’s, Alzheimer’s, Amyotropic Lateral Sclerosis and other CNS disorders.
This type of disorders affect over 3 billion people worldwide, and effective disease-modifying treatments remain limited. Increasing scientific evidence highlights neuroinflammation as a key biological driver of disease progression, making it an important emerging target for therapeutic innovation.
Under the agreement, the parties will combine AndzonBio2’s expertise in early drug development and translational strategy with Cambridge’s world-leading neuroscience capabilities and ADDI’s drug discovery platform. Together, they aim to progress a novel, first-in-class therapeutic program designed to modulate key pathways involved in neuroinflammatory processes. The program is based on cutting-edge biology and represents an emerging area of significant scientific and commercial interest.
Loic Lhuillier, CEO of AndzonBio2 said:
“We are thrilled to enter this collaboration with the ADDI at Cambridge. Neuroinflammation is at the core of many severe brain diseases and new therapeutic solutions are urgently needed. By combining our complementary strengths, we have a unique opportunity to accelerate the development of a highly innovative therapeutic approach with the potential to change the treatment landscape for patients”
At Cambridge Enterprise, when commercialising transformative technologies, we need to find the right partner to deliver the best outcome for University research. It’s about finding the right fit. That generally means looking for partners with a specific area of expertise and an experienced team. Together, we have better chances of progressing a piece of research into a service or product that will ultimately have a societal impact.
In this case, AndzonBio2 has a strategic focus on neuroinflammation and the expertise in central nervous system (CNS) drug development needed to progress this programme through preclinical into clinical development, in collaboration with Alzheimer’s Research UK’s ALBORADA Drug Discovery Institute at the University. Cambridge Enterprise has granted AndzonBio2 an exclusive option to license the intellectual property from the programme, including the University collaboration. The partnership is structured to efficiently integrate academic discovery with industry-grade drug development, enabling rapid progress toward candidate nomination and future clinical testing.
Professor John Skidmore, Chief Scientific Officer of the ALBORADA Drug Discovery Institute at the University of Cambridge, said:
“We are delighted to collaborate with AndzonBio2 on this promising project. This partnership exemplifies our commitment to translating cutting-edge neuroscience into impactful therapies. AndzonBio2 brings a focused expertise in neuroinflammation and drug development that will be instrumental in driving this promising programme forward.”
Dr Phil Elstob, Senior Commercialisation Director, said:
“Whilst the programme is currently at an early stage and yet to be tested clinically, the therapeutic potential of this work is significant and this agreement with AndzonBio2 will accelerate its development, potentially becoming a much-needed alternative for patients with neuroinflammatory conditions such as Parkinson’s Disease.”
The agreement reinforces Cambridge’s and ADDI’s mission to catalyse innovation in neuroscience through partnerships with organisations capable of translating discoveries into real-world therapeutic opportunities.
